0000899243-20-021550.txt : 20200805 0000899243-20-021550.hdr.sgml : 20200805 20200805184747 ACCESSION NUMBER: 0000899243-20-021550 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200803 FILED AS OF DATE: 20200805 DATE AS OF CHANGE: 20200805 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kumar Neil CENTRAL INDEX KEY: 0001742485 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38959 FILM NUMBER: 201079133 MAIL ADDRESS: STREET 1: C/O EIDOS THERAPEUTICS, INC. STREET 2: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BridgeBio Pharma, Inc. CENTRAL INDEX KEY: 0001743881 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: (650) 391-9740 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 FORMER COMPANY: FORMER CONFORMED NAME: BridgeBio Pharma LLC DATE OF NAME CHANGE: 20180618 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-03 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001742485 Kumar Neil C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET PALO ALTO CA 94301 1 1 0 0 CEO and President Common Stock 2020-08-03 4 S 0 63017 27.2277 D 2102355 I See footnote Common Stock 2020-08-03 4 S 0 3040 28.1244 D 2099315 I See footnote Common Stock 2020-08-04 4 S 0 7184 26.7046 D 2092131 I See footnote Common Stock 2020-08-04 4 S 0 6759 27.3582 D 2085372 I See footnote Common Stock 4685725 D Common Stock 927686 I See footnote This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. Represents the weighted average sale price of the shares sold from $26.77 to $27.72 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2, 4, 5 and 6. The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Represents the weighted average sale price of the shares sold from $27.78 to $28.57 per share. Represents the weighted average sale price of the shares sold from $26.16 to $27.15 per share. Represents the weighted average sale price of the shares sold from $27.16 to $27.59 per share. The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. /s/ Tara Condon, Attorney-in-Fact 2020-08-04